These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19049753)

  • 1. Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation.
    Ford RL; Mains IM; Hilton EJ; Reeves ST; Stroud RE; Crawford FA; Ikonomidis JS; Spinale FG
    Ann Thorac Surg; 2008 Nov; 86(5):1576-83. PubMed ID: 19049753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective endothelin-A receptor inhibition after cardiac surgery: a safety and feasibility study.
    Ikonomidis JS; Hilton EJ; Payne K; Harrell A; Finklea L; Clark L; Reeves S; Stroud RE; Leonardi A; Crawford FA; Spinale FG
    Ann Thorac Surg; 2007 Jun; 83(6):2153-60; discussion 2161. PubMed ID: 17532415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics.
    Toole JM; Ikonomidis JS; Szeto WY; Zellner JL; Mulcahy J; Deardorff RL; Spinale FG
    J Thorac Cardiovasc Surg; 2010 Mar; 139(3):646-54. PubMed ID: 20074751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of post-cardiopulmonary bypass acute kidney injury by endothelin A receptor blockade.
    Patel NN; Toth T; Jones C; Lin H; Ray P; George SJ; Welsh G; Satchell SC; Sleeman P; Angelini GD; Murphy GJ
    Crit Care Med; 2011 Apr; 39(4):793-802. PubMed ID: 21220998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
    MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
    Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-alpha production in whole blood after cardiopulmonary bypass: downregulation caused by circulating cytokine-inhibitory activities.
    Börgermann J; Friedrich I; Flohé S; Spillner J; Majetschak M; Kuss O; Sablotzki A; Feldt T; Reidemeister JC; Schade FU
    J Thorac Cardiovasc Surg; 2002 Sep; 124(3):608-17. PubMed ID: 12202878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass.
    Joffs C; Walker CA; Hendrick JW; Fary DJ; Almany DK; Davis JN; Goldberg AT; Crawford FA; Spinale FG
    J Thorac Cardiovasc Surg; 2001 Aug; 122(2):365-70. PubMed ID: 11479511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble tumor necrosis factor receptor p55 predicts cytokinemia and systemic inflammatory response after cardiopulmonary bypass.
    el-Barbary M; Khabar KS
    Crit Care Med; 2002 Aug; 30(8):1712-6. PubMed ID: 12163781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dynamic change of tumor necrosis factor and endothelin during perioperative period in patients undergoing coronary artery bypass grafting].
    Wen S; Wang J; Zhang C
    Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(23):1450-2. PubMed ID: 11930620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and urinary cytokine homeostasis and renal function during cardiac surgery without cardiopulmonary bypass.
    Gormley SM; McBride WT; Armstrong MA; McClean E; MacGowan SW; Campalani G; McMurray TJ
    Cytokine; 2002 Jan; 17(2):61-5. PubMed ID: 11886172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    Horn EM; Widlitz AC; Barst RJ
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.
    Barst RJ
    Expert Opin Pharmacother; 2007 Jan; 8(1):95-109. PubMed ID: 17163810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
    Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
    Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N;
    J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged anti-hypertensive effects of oral sitaxsentan, a selective ET(A) endothelin receptor antagonist, in spontaneoulsy hypertensive hamsters.
    Rubinstein I
    Cardiovasc Drugs Ther; 2006 Oct; 20(5):387-90. PubMed ID: 17043751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of interleukin-6, interleukin-8, interleukin-10, and tumor necrosis factor-α, renal function biochemical parameters and clinical outcomes in pediatric cardiopulmonary bypass surgery.
    Gorjipour F; Totonchi Z; Gholampour Dehaki M; Hosseini S; Tirgarfakheri K; Mehrabanian M; Mortazian M; Arasteh Manesh S; Rahab M; Shafighnia S; Taiyari S; Gorjipour F
    Perfusion; 2019 Nov; 34(8):651-659. PubMed ID: 31027462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective and mixed endothelin receptor antagonism in cardiovascular disease.
    Dhaun N; Pollock DM; Goddard J; Webb DJ
    Trends Pharmacol Sci; 2007 Nov; 28(11):573-9. PubMed ID: 17950470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations.
    Seghaye M; Duchateau J; Bruniaux J; Demontoux S; Bosson C; Serraf A; Lecronier G; Mokhfi E; Planche C
    J Thorac Cardiovasc Surg; 1996 Mar; 111(3):545-53. PubMed ID: 8601968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changes and effects of the plasma levels of tumor necrosis factor after coronary artery bypass surgery with cardiopulmonary bypass.
    Abacilar F; Dogan OF; Duman U; Ucar I; Demircin M; Ersoy U; Dogan R; Boke E
    Heart Surg Forum; 2006; 9(4):E703-9. PubMed ID: 16844625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.